Clinical trials transformation

Clinical trials are an essential step in ensuring the safety and efficacy of new therapies. Advances in science and technology offer a deeply impactful opportunity to transform how studies are designed and delivered, creating a new breed of trials that produce results in dramatically reduced timescales.

The next generation of clinical trials must be human-centred, secure, and compliant, and driven by data to meet growing demand and complexity. A clear vision – supported by data, integrated technology platforms, and a bold, human-centered approach – will unlock value for all.

Survey

Understanding the perceptions and potential of clinical research

Can you risk ignoring the 65 percent of people who want to share data to aid clinical research? Access our exclusive survey of 2,000 US respondents.

Working together

Our experienced teams partner with clients to transform clinical research from initial protocol design to post-market success. Through real-world experience of change-making across the development process, innovative digital thinking, and cross-sector connections, we develop new platforms, share risk, and accelerate the delivery of the next generation of clinical trials

Talk to us about

Unleashing the power of data

Digitalise trials, build new platforms, and enable end-to-end data flow to create safe, successful clinical trials. Reduce time to market through the integration of EHR, real-world, and historical trial data, including pre-clinical and clinical metrics.

Enabling the next generation of trials

Support the design and operation of new trial types including adaptive, decentralised, and remote models that produce valuable results at pace.

Becoming truly human-centred

Drive greater participant and patient representation and adherence through more effective recruitment strategies and patient-centric engagement that build trust and confidence.

Enhancing security and reducing regulatory risk

Maintain constant compliance by understand the evolving regulatory landscape, creating security and compliance approaches that align to necessary legal and regulatory frameworks.

Understanding and improving performance

Assess and monitor study and portfolio performance through robust modelling. Analyse metrics, set incentives, and establish benchmarking to develop new, value-based models that focus on patients and participants to drive effective outcomes.

Predicting and pre-empting change

Use simulation technologies such as digital twins to understand the impact of change on digital models before investing in real-world implementation, saving significant costs. Benefit from interoperable IT and data management infrastructure, infused with artificial intelligence and machine learning capabilities, to drive a proactive, pre-emptive approach.

Get in touch

Featured insight

Woman seated on row of chairs reading document

Report

Expert views

AI has huge potential to transform the end-to-end trials process. Ethical concerns and regulatory uncertainty will play a significant role in influencing how quickly the industry is able to move, and there will be the potential for new organizations to break out in this space. These will be data-rich organizations that build their platforms with their partners to generate trust and that best solve the problem of validating continually evolving models.”

Charlie Paterson Clinical development

Read the article

Leaders will be pressed to get more value out of the data and platforms they have already invested in so as not to limit or slow down programs already in flight. Given this, what can leaders do to prepare and make incremental steps toward transformation now?”

Kelsey Jakee Life sciences

Read the article

Although aligning on a vision, measuring progress, and creating a culture of accountability doesn’t happen overnight, it is imperative that we keep pushing forward to improve the representation of diverse populations in clinical trials.”

Seema Vadsola Healthcare and life sciences

Read the article

With the level of adoption of decentralised trial methodologies continuing to grow despite the predicted pullback following the lessening of pandemic restrictions, all organisations should be asking how they can do more, and move faster, toward more human-centric trial designs.”

Kieran Reals Clinical development

Read the article

The generation of multiple types of complex organoids along with the innovation in optical setups and omics techniques is providing researchers with new, more extensive raw data that requires novel analytics tools and platforms.”

Hilary Thomas Healthcare and life sciences

Read the article